FRONTEO Inc. (Headquarters: Minato-ku, Tokyo, CEO: Masahiro Morimoto, hereafter FRONTEO) has added a drug discovery support AI "Amanogawa" that visualizes molecules and genes related to diseases in a pathway map. We have released "Amanogawa Pro" which is a combination of "Cascade Eye".

"Cascade Eye" is learning the latest treatise information published in PubMed *.When you enter a disease name, the molecules and genes related to that disease are displayed in a pathway map, and the connections and overall picture of each are analyzed and visualized.Therefore, it is possible to greatly improve the efficiency of target search, and it is difficult to realize by human research such as discovering the possibility of diversion of existing drugs used in different diseases and identifying biomarkers that have not been found so far. Enables an innovative drug discovery approach.

By combining "Cascade Eye" and "Amanogawa" with these functions into one application, it is possible to analyze information on molecules, genes, and diseases from the paper information in a cross-sectional and unified manner. I will. "Amanogawa Pro" will make research on drug discovery and treatment methods more efficient and will greatly speed up new discoveries.

FRONTEO aims to make drug discovery research utilizing our AI a new standard in drug discovery research, and will promote the development of practical drug discovery support AI together with the companies that use it.

* PubMed: A database that allows you to search for articles in the field of biomedical science. Created by NCBI (National Center for Biotechnology Information) in NLM (National Library of Medicine).

■Amanogawaabout URL: https://lifescience.fronteo.com/aidiscovery/amanogawa/

"Amanogawa (trademark / patent pending)" is a paper search AI system equipped with FRONTEO's original AI engine "Concept Encoder (registered trademark: concept encoder ®, reading: concept encoder)".When a researcher inputs a sentence such as a word or hypothesis of interest, "Concept Encoder" instantly detects the article related to the input content from the large number of articles published in PubMed.

Since the search results are plotted in a map according to the similarity between the articles, you can check the relevance at a glance, and drag the article information detected on the map to narrow down the search, which is a visual that has never been seen before. You can search for articles.In addition, you can sort the search results in order of relevance and list their abstracts, greatly streamlining your article search.This makes it possible to discover events and new drug targets from a perspective that is difficult for humans to notice.

■FRONTEOabout　URL: https://www.fronteo.com/

FRONTEO supports corporate business by extracting meaningful and important information from a huge amount of text data using the in-house developed AI engine "KIBIT®" and "concept encoder®" that specialize in natural language processing. It is a data analysis company. Since its establishment in August 2003, it has been expanding globally to Japan, the United States, South Korea, and Taiwan, focusing on legal tech businesses such as "e-discovery (electronic discovery)" and "digital forensic investigation" that support international litigation of companies. Has been deployed. From 8, based on the AI ​​technology cultivated in the legal tech business, we will expand the business field to the life science field and business intelligence field, and use AI to "turn text data into knowledge" to support drug discovery. We contribute to solving various corporate issues such as dementia diagnosis support, financial, personnel, and sales support. Listed on TSE Mothers on June 2014, 2007.The capital is 6 thousand yen (as of March 26, 2,568,651).